Mendelian randomization study for the roles of IL-18 and IL-1 receptor antagonist in the development of inflammatory bowel disease
- 14 July 2022
- journal article
- research article
- Published by Elsevier in International Immunopharmacology
- Vol. 110, 109020
Abstract
No abstract availableKeywords
Funding Information
- Jilin University
- Fundamental Research Funds for the Central Universities
- CAMS (3332021007)
This publication has 49 references indexed in Scilit:
- Host–microbe interactions have shaped the genetic architecture of inflammatory bowel diseaseNature, 2012
- NLRP6 Inflammasome Regulates Colonic Microbial Ecology and Risk for ColitisCell, 2011
- Interleukin-18 Gene Polymorphisms in Tunisian Patients with Inflammatory Bowel DiseaseDigestion, 2011
- Unravelling the pathogenesis of inflammatory bowel diseaseNature, 2007
- Association of interleukin-1 receptor-associated kinase M (IRAK-M) and inflammatory bowel diseasesScandinavian Journal of Gastroenterology, 2007
- A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease GeneScience, 2006
- −137 (G/C) IL-18 promoter polymorphism in patients with inflammatory bowel diseaseScandinavian Journal of Gastroenterology, 2005
- Measuring inconsistency in meta-analysesBMJ, 2003
- Therapeutic Potential of Interleukin-1 Receptor Antagonist in Inflammatory Bowel Disease.The Kurume Medical Journal, 1998
- Increased Circulating Levels of Interleukin-1 Receptor Antagonist in Patients with Inflammatory Bowel Disease.The Kurume Medical Journal, 1998